About this trial

The purpose of this study is to assess the long-term safety and performance of the LEGION Medial Stabilized insert and to generate clinical evidence to support and maintain product registration in global markets.

Eligibility criteria

Qualifiers

A). Prospective Subjects: Subject needing primary Total Knee Arthroplasty (TKA) due to degenerative joint disease (primary diagnosis of osteoarthritis), post-traumatic arthritis or inflammatory arthritis.

Pre-operative Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) has been obtained

Post-operative radiographs have been obtained, or these can be collected prospectively in window per schedule of events

12-month post-operative KOOS JR have been obtained, or these can be collected prospectively in window per schedule of events

Disqualifiers

Subject received revision TKA on the contralateral knee for a previously failed TKA, or Unicondylar Knee Arthroplasty (UKA).

Subject has a Body Mass Index (BMI) ≥ 40 at pre-operative visit.

Subject has ipsilateral hip arthritis resulting in flexion contracture of the hip joint.

At the time of surgery, subject has one or more of the following arthroplasties that are not fully healed and/or well-functioning, in the opinion of the Investigator: Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; contralateral primary TKA or UKA.

Trial design

Treatments tested in this trial

  • Cemented CoCr
  • Cemented Oxinium
  • Cementless

Treatment groups

144 Participants
are divided into 3 treatment groups

Locations

6
Arizona
The Core Institute85023, Phoenix United States
Florida
Rothman Orthopedics-Advent Health32803, Orlando United States
Massachusetts
Newton Wellesley Hospital02462, Newton United States
New York
New York University Hospital10016, New York United States

Sponsors and collaborators

Smith & Nephew, Inc.

Lead sponsor